J García-Lorenzo1, N Farre2, A Codina3, O Gallego4, M De Vega2, X León3. 1. Otorhinolaryngology Department, Hospital de la Santa Creu I Sant Pau, C. Sant Antoni Maria Claret 167, 08025, Barcelona, Spain. jgarcial@santpau.cat. 2. Radiation Oncology Department, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain. 3. Otorhinolaryngology Department, Hospital de la Santa Creu I Sant Pau, C. Sant Antoni Maria Claret 167, 08025, Barcelona, Spain. 4. Medical Oncology Department, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain.
Abstract
PURPOSE: Over the past years, radiotherapy techniques have changed significantly. The impact of these changes in the management of nasopharyngeal carcinoma (NPC) has not been fully evaluated. METHODS/PATIENTS: Between 1984 and 2014, 223 NPC were diagnosed in our hospital. Prior to 2000, patients were treated with 2D treatment plan (RT2D) that evolved to 3D schemes thereafter (RT3D). RESULTS: Tumors in the RT3D period showed significantly lower stages than those in the RT2D period. 5-year cause-specific survival improved from 55.7% (95% CI: 46.7-64.7%) in the RT2D period to 78.7% (95% CI: 68.7-88.7%) in the RT3D period (P = 0.006). This difference was greater for non-keratinizing NPC, where specific survival went from 63.2% (95% CI: 52.2-74.2%) to 84.4% (95% CI: 74.4-94.4%) (P = 0.014). CONCLUSION: Recent changes in treatment strategies including concurrent chemoradiation and 3D radiotherapy may have impacted in better survival for NPC. Improved imaging techniques may have contributed by earlier detection and better treatment planning.
PURPOSE: Over the past years, radiotherapy techniques have changed significantly. The impact of these changes in the management of nasopharyngeal carcinoma (NPC) has not been fully evaluated. METHODS/PATIENTS: Between 1984 and 2014, 223 NPC were diagnosed in our hospital. Prior to 2000, patients were treated with 2D treatment plan (RT2D) that evolved to 3D schemes thereafter (RT3D). RESULTS:Tumors in the RT3D period showed significantly lower stages than those in the RT2D period. 5-year cause-specific survival improved from 55.7% (95% CI: 46.7-64.7%) in the RT2D period to 78.7% (95% CI: 68.7-88.7%) in the RT3D period (P = 0.006). This difference was greater for non-keratinizing NPC, where specific survival went from 63.2% (95% CI: 52.2-74.2%) to 84.4% (95% CI: 74.4-94.4%) (P = 0.014). CONCLUSION: Recent changes in treatment strategies including concurrent chemoradiation and 3D radiotherapy may have impacted in better survival for NPC. Improved imaging techniques may have contributed by earlier detection and better treatment planning.
Authors: M A Hunt; M J Zelefsky; S Wolden; C S Chui; T LoSasso; K Rosenzweig; L Chong; S V Spirou; L Fromme; M Lumley; H A Amols; C C Ling; S A Leibel Journal: Int J Radiat Oncol Biol Phys Date: 2001-03-01 Impact factor: 7.038
Authors: Vincent Grégoire; Peter Levendag; Kian K Ang; Jacques Bernier; Marijel Braaksma; Volker Budach; Cliff Chao; Emmanuel Coche; Jay S Cooper; Guy Cosnard; Avraham Eisbruch; Samy El-Sayed; Bahman Emami; Cai Grau; Marc Hamoir; Nancy Lee; Philippe Maingon; Karin Muller; Hervé Reychler Journal: Radiother Oncol Date: 2003-12 Impact factor: 6.280
Authors: Melina Arnold; Maarten A Wildeman; Otto Visser; Henrike E Karim-Kos; Jaap M Middeldorp; Renske Fles; I Bing Tan; Jan Willem Coebergh Journal: Oral Oncol Date: 2012-10-22 Impact factor: 5.337
Authors: Katelyn O Stepan; Angela L Mazul; S Andrew Skillington; Randal C Paniello; Jason T Rich; Jose P Zevallos; Ryan S Jackson; Patrik Pipkorn; Sean Massa; Sidharth V Puram Journal: Head Neck Date: 2021-02-23 Impact factor: 3.821